Abstract 29P
Background
Early prediction of tumor response to therapy is essential for individualized treatment and sparing non-responders needless harm. A relationship has recently been found between pathologic response in breast cancer (BC) and a measure of cell loss based on serum levels of thymidine kinase 1 (sTK1), a macromolecule released when proliferating tumor cells are disrupted, and tumor volume. Objective: To establish whether the predictive power of this cell-loss metric can be further improved by baseline tumor characteristics.
Methods
Fifty-eight women with localized BC received neoadjuvant epirubicin/docetaxel in 6 cycles, supplemented with bevacizumab in cycle 3-6. The cell-loss metric, defined as the ratio between sTK1 (ng/ml) and tumor volume (cm3), was obtained prior to and 48h after cycle 2. The predictive value of this metric, and the improvement by adding routine baseline markers, was evaluated using pathologic response as endpoint (16 complete responses (pCR); 42 remaining tumors).
Results
Compared to baseline (median = 0.285 ng / ml), sTk1 increased 2-fold before cycle 2 and 3-fold 48h after cycle 2 while tumor volume (baseline 105 cm3) decreased by 70%. The cell loss method increased from 0.0032 units (IQR 0.0015-0.0099) to 0.0166 (0.0064-0.0423) and 0.0232 (0.0095-0.053), respectively, showing a strong association with pathological response (p = 0.002). Combination with histological markers, and especially the progesterone receptor, significantly improved the prediction of pCR, achieving positive and negative predictive values of 81% and 93%.
Conclusions
The usefulness of tumor markers in blood can be increased by combining them with other tumor properties. Thus, in neoadjuvant treatment of BC the cell-loss metric, which relates sTK1 to tumor volume, has been noticed as a predictor of pathologic response. Here we found that adding certain established tumor markers significantly improved the predictive power of the metric. Early prediction of tumor response makes the cell-loss metric potentially useful in personalized oncology and in the evaluation in new therapeutic modalities.
Clinical trial identification
PROMIX: NCT00957125.
Editorial acknowledgement
Legal entity responsible for the study
Thomas Hatschek, MD, PhD, Karolinska University Hospital.
Funding
Has not received any funding.
Disclosure
B. Tribukait: Shareholder / Stockholder / Stock options, minor stock owner: AroCell Ab.
Resources from the same session
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract